Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q4 FY24 results · Jan–Mar 2024
Tatva Chintan Pharma Chem reported revenue from operations of ₹98.27 crore (down 21.1% from Q4 FY23) and net profit of ₹9.61 crore (down 43.3% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 98.27 | 124.51 | −21.1% | 84.21 | +16.7% |
| Other income | 4.53 | 0.84 | +435.9% | 1.21 | +274.2% |
| Total income | 102.79 | 125.36 | −18.0% | 85.42 | +20.3% |
| Profit before tax | 13.69 | 7.80 | +75.5% | 5.24 | +161.1% |
| Net profit for the period | 9.61 | 16.95 | −43.3% | 3.46 | +178.3% |
| EPS, basic (₹) | 4.11 | 7.65 | −46.3% | 1.48 | +177.7% |
| Net margin (%) | 9.8 | 13.6 | 4.1 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 93.93 | 119.41 | −21.3% | 86.07 | +9.1% |
| Other income | 4.53 | 0.78 | +478.2% | 1.21 | +274.4% |
| Total income | 98.46 | 120.19 | −18.1% | 87.28 | +12.8% |
| Profit before tax | 12.28 | 6.89 | +78.2% | 6.56 | +87.0% |
| Net profit for the period | 8.25 | 16.15 | −48.9% | 4.65 | +77.3% |
| EPS, basic (₹) | 3.52 | 7.29 | −51.7% | 1.99 | +76.9% |
| Net margin (%) | 8.8 | 13.5 | 5.4 |
Consolidated
- Filed with BSE
- 11 May 2024, 11:49 IST
- Board meeting
- 03 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 May 2024, 11:49 IST
- Board meeting
- 03 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE